Pancreatic Cancer Action Network Grant Recipient Costas Lyssiotis, PhD

Home Research Research Grants Program Grants Awarded All Grant Recipients 2013 Pancreatic Cancer Action Network Grant Recipient Costas Lyssiotis, PhD

GRANTEE: Costas Lyssiotis, PhD

Institution: Weill Cornell Medical College
Research Project: Exploration and Targeting of Metabolic Dependencies in Pancreatic Cancer
Award: Pancreatic Cancer Action Network – AACR Pathway to Leadership Grant
Award Period: July 1, 2013 – June 30, 2018
Amount: $600,000

Click here to download Dr. Lyssiotis’s Grant Snapshot (pdf)

Biographical Highlights
Dr. Lyssiotis obtained his bachelor’s degree in chemistry and biochemistry from the University of Michigan and his PhD in chemical biology at The Scripps Research Institute in La Jolla, CA. In 2010, he joined the laboratory of Lewis Cantley, PhD at Harvard Medical School as the Amgen fellow of the Damon Runyon Cancer Research Foundation. He is currently a senior postdoctoral fellow in Dr. Cantley’s laboratory at Weill Cornell Medical College. His research is focused on understanding the biochemical pathways and metabolic requirements that enable pancreatic tumor growth and, in particular, how this information can be used to design targeted therapies to treat this dreadful disease. For the initial phase of the project outlined in his grant proposal, Dr. Lyssiotis will be co-mentored by Dr. Cantley and Alec Kimmelman, MD, PhD, recipient of a Career Development Award from the Pancreatic Cancer Action Network in 2010.

Project Overview
Like all cells in the body, pancreatic cancer cells depend on the nutrients we consume to grow and survive. Treating cancer by targeting the way that malignant cells take in and use such nutrients (their metabolism) has emerged as a highly promising therapeutic strategy. However, because normal cells and cancer cells often require the same energy sources and metabolic pathways, designing effective metabolism-based cancer therapies has been challenging. In 2012 and 2013, Dr. Lyssiotis was a lead author on two papers in the prestigious journals Cell and Nature uncovering new roles for the mutated protein K-Ras as a master regulator of pancreatic cancer metabolism. Importantly, these studies have revealed new therapeutic targets and suggested new ways to treat pancreatic cancer.

In this proposed project, Dr. Lyssiotis will further evaluate the dependence of pancreatic cancer cells on the nutrients glucose (sugar) and glutamine (a prevalent amino acid, or building block of proteins). Since K-Ras has proven to be an elusive target, Dr. Lyssiotis will explore therapeutic targets downstream of K-Ras. Specifically, he will focus on determining how mutant K-Ras instructs pancreatic cancer cells to break down these two essential nutrients and how the energy derived is used to build DNA and to defend against harmful reactive oxygen species. Dr. Lyssiotis aims to use his understanding of these newly identified pancreatic cancer-specific metabolism pathways to develop innovative targeted therapies that selectively eliminate diseased cells.

Wage Hope With Us

Join us to double pancreatic cancer survival by 2020.





shop purple logo

Gear, apparel, accessories and more to show off your purple pride.


Shop Now 

©2018 Pancreatic Cancer Action Network. All rights reserved. Terms of Use | Privacy Policy


Pancreatic Cancer Action Network®, PanCAN®, PurpleStride®, Wage Hope®, Know Your Tumor®, Powerful Knowledge. Personal Treatment.®, Precision Promise℠ and Demand Better For Patients. For Survival.℠ are the trademarks of the Pancreatic Cancer Action Network, Inc.


The Pancreatic Cancer Action Network is registered as a 501©3 nonprofit organization. Contributions to the Pancreatic Cancer Action Network are tax-deductible to the extent permitted by law. The Pancreatic Cancer Action Network’s tax identification number is #33-0841281.